Arcus Biosciences, Inc.

NYSE:RCUS Stock Report

Market Cap: US$2.6b

Arcus Biosciences Valuation

Is RCUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of RCUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: RCUS ($20.03) is trading below our estimate of future cash flow value ($130.63)

Significantly Below Future Cash Flow Value: RCUS is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RCUS?

Key metric: As RCUS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RCUS. This is calculated by dividing RCUS's market cap by their current revenue.
What is RCUS's PS Ratio?
PS Ratio10.3x
SalesUS$240.00m
Market CapUS$2.60b

Price to Sales Ratio vs Peers

How does RCUS's PS Ratio compare to its peers?

The above table shows the PS ratio for RCUS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average24.8x
BEAM Beam Therapeutics
43.8x51.33%US$2.7b
TWST Twist Bioscience
7.4x13.38%US$3.0b
RXRX Recursion Pharmaceuticals
42.4x52.84%US$2.0b
VCYT Veracyte
5.6x10.12%US$2.9b
RCUS Arcus Biosciences
10.3x27.38%US$2.6b

Price-To-Sales vs Peers: RCUS is good value based on its Price-To-Sales Ratio (10.3x) compared to the peer average (24.8x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does RCUS's PS Ratio compare vs other companies in the US Biotechs Industry?

127 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.7x-1.14%US$27.21b
BMRN BioMarin Pharmaceutical
3.5x6.66%US$11.07b
PTCT PTC Therapeutics
3.3x1.30%US$5.93b
ALKS Alkermes
3.6x8.96%US$5.64b
RCUS 10.3xIndustry Avg. 10.9xNo. of Companies127PS01632486480+
127 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: RCUS is good value based on its Price-To-Sales Ratio (10.3x) compared to the US Biotechs industry average (11.5x).

Price to Sales Ratio vs Fair Ratio

What is RCUS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RCUS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.3x
Fair PS Ratio1x

Price-To-Sales vs Fair Ratio: RCUS is expensive based on its Price-To-Sales Ratio (10.3x) compared to the estimated Fair Price-To-Sales Ratio (1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RCUS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$20.03
US$33.00
+64.75%
23.55%US$47.00US$20.00n/a10
Jan ’27US$23.83
US$32.10
+34.70%
27.70%US$47.00US$16.00n/a10
Dec ’26US$26.10
US$33.22
+27.29%
35.38%US$56.00US$16.00n/a9
Nov ’26US$19.72
US$30.20
+53.14%
42.94%US$56.00US$14.00n/a10
Oct ’26US$13.48
US$28.91
+114.46%
45.02%US$52.00US$12.00n/a11
Sep ’26US$10.59
US$28.91
+172.98%
45.02%US$52.00US$12.00n/a11
Aug ’26US$9.16
US$28.18
+207.66%
43.03%US$46.00US$12.00n/a11
Jul ’26US$8.36
US$28.18
+237.10%
43.03%US$46.00US$12.00n/a11
Jun ’26US$8.93
US$28.18
+215.59%
43.03%US$46.00US$12.00n/a11
May ’26US$8.62
US$30.36
+252.25%
39.50%US$46.00US$14.00n/a11
Apr ’26US$7.71
US$32.55
+322.12%
30.29%US$46.00US$17.00n/a11
Mar ’26US$10.89
US$32.55
+198.86%
30.29%US$46.00US$17.00n/a11
Feb ’26US$12.90
US$33.20
+157.36%
28.25%US$46.00US$20.00US$21.0410
Jan ’26US$14.89
US$33.20
+122.97%
28.25%US$46.00US$20.00US$23.8310
Dec ’25US$15.44
US$33.20
+115.03%
28.25%US$46.00US$20.00US$26.1010
Nov ’25US$15.50
US$33.10
+113.55%
28.26%US$46.00US$20.00US$19.7210
Oct ’25US$15.42
US$33.13
+114.82%
25.55%US$46.00US$23.00US$13.488
Sep ’25US$17.12
US$33.13
+93.49%
25.55%US$46.00US$23.00US$10.598
Aug ’25US$15.71
US$33.89
+115.72%
23.25%US$44.00US$24.00US$9.169
Jul ’25US$15.30
US$38.56
+152.00%
33.95%US$70.00US$24.00US$8.369
Jun ’25US$15.07
US$39.00
+158.79%
34.70%US$70.00US$24.00US$8.939
May ’25US$15.50
US$38.89
+150.90%
34.74%US$70.00US$24.00US$8.629
Apr ’25US$18.48
US$39.67
+114.65%
34.24%US$70.00US$24.00US$7.719
Mar ’25US$19.10
US$39.67
+107.68%
34.24%US$70.00US$24.00US$10.899
Feb ’25US$15.85
US$40.22
+153.77%
32.28%US$70.00US$25.00US$12.909
US$33
Fair Value
39.3% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/05 20:11
End of Day Share Price 2026/02/05 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arcus Biosciences, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Jason ZemanskyBofA Global Research
Li Wang WatsekCantor Fitzgerald & Co.